513 related articles for article (PubMed ID: 37274062)
1. Study of tumor necrosis factor receptor in the inflammatory bowel disease.
Souza RF; Caetano MAF; Magalhães HIR; Castelucci P
World J Gastroenterol; 2023 May; 29(18):2733-2746. PubMed ID: 37274062
[TBL] [Abstract][Full Text] [Related]
2. Effects of bovine tumor necrosis factor alpha decoy receptors on cell death and inflammatory cytokine kinetics: potential for bovine inflammation therapy.
Fujisawa S; Konnai S; Okagawa T; Maekawa N; Tanaka A; Suzuki Y; Murata S; Ohashi K
BMC Vet Res; 2019 Feb; 15(1):68. PubMed ID: 30819151
[TBL] [Abstract][Full Text] [Related]
3. Pharmacodynamic mechanisms behind a refractory state in inflammatory bowel disease.
Goll R; Moe ØK; Johnsen KM; Meyer R; Friestad J; Gundersen MD; Kileng H; Johnsen K; Florholmen JR
BMC Gastroenterol; 2022 Nov; 22(1):464. PubMed ID: 36384462
[TBL] [Abstract][Full Text] [Related]
4. TNF-
Gane JM; Stockley RA; Sapey E
J Immunol Res; 2016; 2016():1079851. PubMed ID: 27747245
[TBL] [Abstract][Full Text] [Related]
5. Serum inter-alpha-trypsin inhibitor heavy chain 4 in patients with inflammatory bowel disease: correlation with disease risk, inflammation, activity, and its variation after treatment.
Wen N; Zhao N; Xu H; Zhao Y; Ma J
Ir J Med Sci; 2022 Oct; 191(5):2105-2111. PubMed ID: 34843071
[TBL] [Abstract][Full Text] [Related]
6. Antibodies against tumor necrosis factor (TNF) induce T-cell apoptosis in patients with inflammatory bowel diseases via TNF receptor 2 and intestinal CD14⁺ macrophages.
Atreya R; Zimmer M; Bartsch B; Waldner MJ; Atreya I; Neumann H; Hildner K; Hoffman A; Kiesslich R; Rink AD; Rau TT; Rose-John S; Kessler H; Schmidt J; Neurath MF
Gastroenterology; 2011 Dec; 141(6):2026-38. PubMed ID: 21875498
[TBL] [Abstract][Full Text] [Related]
7. TNF Receptor 1 Promotes Early-Life Immunity and Protects against Colitis in Mice.
Liu CY; Tam SS; Huang Y; Dubé PE; Alhosh R; Girish N; Punit S; Nataneli S; Li F; Bender JM; Washington MK; Polk DB
Cell Rep; 2020 Oct; 33(3):108275. PubMed ID: 33086075
[TBL] [Abstract][Full Text] [Related]
8. Proteolytic cleavage and loss of function of biologic agents that neutralize tumor necrosis factor in the mucosa of patients with inflammatory bowel disease.
Biancheri P; Brezski RJ; Di Sabatino A; Greenplate AR; Soring KL; Corazza GR; Kok KB; Rovedatti L; Vossenkämper A; Ahmad N; Snoek SA; Vermeire S; Rutgeerts P; Jordan RE; MacDonald TT
Gastroenterology; 2015 Nov; 149(6):1564-1574.e3. PubMed ID: 26170138
[TBL] [Abstract][Full Text] [Related]
9. Cytokine tumor necrosis factor-alpha A promoter gene polymorphism at position -308 G-->A and pediatric inflammatory bowel disease: implications in ulcerative colitis and Crohn's disease.
Sýkora J; Subrt I; Dìdek P; Siala K; Schwarz J; Machalová V; Varvarovská J; Pazdiora P; Pozler O; Stozický F
J Pediatr Gastroenterol Nutr; 2006 May; 42(5):479-87. PubMed ID: 16707968
[TBL] [Abstract][Full Text] [Related]
10. Protective role of tumor necrosis factor (TNF) receptors in chronic intestinal inflammation: TNFR1 ablation boosts systemic inflammatory response.
Wang Y; Han G; Chen Y; Wang K; Liu G; Wang R; Xiao H; Li X; Hou C; Shen B; Guo R; Li Y; Chen G
Lab Invest; 2013 Sep; 93(9):1024-35. PubMed ID: 23897411
[TBL] [Abstract][Full Text] [Related]
11. Development, validation and implementation of an in vitro model for the study of metabolic and immune function in normal and inflamed human colonic epithelium.
Pedersen G
Dan Med J; 2015 Jan; 62(1):B4973. PubMed ID: 25557335
[TBL] [Abstract][Full Text] [Related]
12. Altered Intestinal ACE2 Levels Are Associated With Inflammation, Severe Disease, and Response to Anti-Cytokine Therapy in Inflammatory Bowel Disease.
Potdar AA; Dube S; Naito T; Li K; Botwin G; Haritunians T; Li D; Casero D; Yang S; Bilsborough J; Perrigoue JG; Denson LA; Daly M; Targan SR; Fleshner P; Braun J; Kugathasan S; Stappenbeck TS; McGovern DPB
Gastroenterology; 2021 Feb; 160(3):809-822.e7. PubMed ID: 33160965
[TBL] [Abstract][Full Text] [Related]
13. Indicators of suboptimal response to anti-tumor necrosis factor therapy in patients from China with inflammatory bowel disease: results from the EXPLORE study.
Li J; Liu Z; Hu P; Wen Z; Cao Q; Zou X; Chen Y; Wang Y; Zhong J; Shen X; Demuth D; Fadeeva O; Xie L; Chen J; Qian J
BMC Gastroenterol; 2022 Feb; 22(1):44. PubMed ID: 35120446
[TBL] [Abstract][Full Text] [Related]
14. Opposite effects of interferon regulatory factor 1 and osteopontin on the apoptosis of epithelial cells induced by TNF-α in inflammatory bowel disease.
Tang R; Yang G; Zhang S; Wu C; Chen M
Inflamm Bowel Dis; 2014 Nov; 20(11):1950-61. PubMed ID: 25208103
[TBL] [Abstract][Full Text] [Related]
15. Suboptimal response to tumor necrosis factor antagonists in inflammatory bowel disease in Latin America: EXPLORE LATAM study.
Balderramo D; Yamamoto-Furusho J; Ponce de León E; de María J; Zubiaurre I; Pedreira S; Lis C; Brion L; de Paula JA
Gastroenterol Hepatol; 2024 Jan; 47(1):51-62. PubMed ID: 37062500
[TBL] [Abstract][Full Text] [Related]
16. Secretion imbalance between tumour necrosis factor and its inhibitor in inflammatory bowel disease.
Noguchi M; Hiwatashi N; Liu Z; Toyota T
Gut; 1998 Aug; 43(2):203-9. PubMed ID: 10189845
[TBL] [Abstract][Full Text] [Related]
17. TNF-α and soluble forms of TNF receptors 1 and 2 in the serum of patients with Crohn's disease and ulcerative colitis.
Owczarek D; Cibor D; Głowacki MK; Cieśla A; Mach P
Pol Arch Med Wewn; 2012; 122(12):616-23. PubMed ID: 23160117
[TBL] [Abstract][Full Text] [Related]
18. Serum levels of C1q/TNF-related protein-3 in inflammatory bowel disease patients and its inverse association with inflammatory cytokines and insulin resistance.
Mohamadinarab M; Ahmadi R; Gholamrezayi A; Rahvar F; Naghdalipour M; Setayesh L; Moradi N; Fadaei R; Chamani E; Tavakoli T; Esteghamati A
IUBMB Life; 2020 Aug; 72(8):1698-1704. PubMed ID: 32311832
[TBL] [Abstract][Full Text] [Related]
19. Enhanced secretion of tumour necrosis factor-alpha, IL-6, and IL-1 beta by isolated lamina propria mononuclear cells from patients with ulcerative colitis and Crohn's disease.
Reinecker HC; Steffen M; Witthoeft T; Pflueger I; Schreiber S; MacDermott RP; Raedler A
Clin Exp Immunol; 1993 Oct; 94(1):174-81. PubMed ID: 8403503
[TBL] [Abstract][Full Text] [Related]
20. Management of inflammatory bowel disease beyond tumor necrosis factor inhibitors: novel biologics and small-molecule drugs.
Na SY; Kim YS
Korean J Intern Med; 2022 Sep; 37(5):906-919. PubMed ID: 35945034
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
